The second docetaxel rechallenge for metastatic castration-resistant prostate cancer: a case report

BACKGROUND: Docetaxel combined with prednisone plus androgen deprivation therapy (ADT) is the preferred treatment option for metastatic hormone-sensitive prostate cancer (mHSPC) or metastatic castration-resistant prostate cancer (mCRPC). With the development of next-generation hormonal agents (NHAs)...

Descripción completa

Detalles Bibliográficos
Autores principales: Ning, Wei, Chang, Pengkang, Zheng, Ji, He, Fan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565221/
https://www.ncbi.nlm.nih.gov/pubmed/37829337
http://dx.doi.org/10.3389/fonc.2023.1185530

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565221/
https://www.ncbi.nlm.nih.gov/pubmed/37829337
http://dx.doi.org/10.3389/fonc.2023.1185530

Ejemplares similares